Meritxell Novillo-Font

Meritxell Novillo-Font

Auto-generated profile, based on publicly available information

Meritxell Novillo-Font

Centre Nacional d’Anàlisi Genòmica, CNAG, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Cancer Discovery
Verified
Journal Article
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945–treated metastases underwent a transition from a poor prognosis–associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell–like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell–like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201

6 February 2026
Verified
Other
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
Supplementary Figures S1-S14 related to the manuscript "A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer"

6 February 2026
Verified
Other
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
Analysis of chromatin regulation by RMC-9945. A, Heatmaps and ATAC profile plots of differential peaks for vehicle-treated (n = 4,148) and RMC-9945–treated (n = 898) AKTP MTOs for 48 hours. B, Motif analysis on differential peaks reveals enrichment in members of the JUN/FOS family of TFs for vehicle (left) and LEF/TCF7 family of TFs for RMC-9945 (right). Top 30 significant most enriched motifs are shown. C, Representation (Gaudí plot) for ATAC-seq signal rendered for both the vehicle (left) and RMC-9945 (right), centered at chr6:134,835,000-135,835,000. Emp1 locus highlighted (green dot). All genomic bins within the dashed circle are taken into consideration for the motif search analysis. D, ChromBPNet contribution tracks for vehicle and RMC-9945 highlighting three (of six) AP1 motifs open in vehicle and closed in RMC-9945. Arcs represent the interaction between the TSS containing 5 kbp bin and those in spatial proximity in the Gaudí plot (dashed circle in C). E, Gaudí plot for ATAC-seq signal rendered for Lgr5 locus, centered at chr10:114,920,000-115,925,000. Same representation as in C. F, ChromBPNet contribution and interaction tracks for vehicle and RMC-9945 highlighting four (of five) TCF7/LEF1 TF-binding sites open in RMC-9945.

6 February 2026
Verified
Other
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
KRASG12D inhibition enforces a Lgr5+ ISC-like transcriptional program in liver metastases. A, Experimental setup of RMC-9945 treatment of liver metastases. Treatment started at day 15, 21, or 25 after inoculation of liver metastases implanted in the spleen (IS) of C57BL/6J mice and continued for 11 days. B, Longitudinal intravital bioluminescence quantification of AKTP MTOs treated with vehicle or RMC-9945. C, Treatment from day 15, day 21, and day 25 of established liver metastases (LiM) generated by injecting AKTP MTOs in the spleen of C57BL/6J mice. Number of liver metastases. Vehicle n = 5 mice, D15 n = 7, D21 n = 8, and D25 = 8. Mean ± SEM; P values are derived from ANOVA followed by two-sided Dunnett tests. D, UMAP visualization of scRNA-seq (n = 11,410) showing vehicle-treated (gray) and RMC-9945–treated (green) cells. Mice were treated from day 21 to day 26 (6 days), and liver metastasis dissected. E, UMAP projection with data points colored by Louvain clusters (resolution 0.6), in which each cluster is represented in a unique color to emphasize the dataset’s underlying structure. F, Bar plot showing the frequency distribution of cells in the vehicle and RMC-9945 groups within each cluster, ordered by their association with CSC, intermediate, or HRC states. Percentages represent the proportion of cells in each group per cluster. G and H, UMAP visualization and violin plot showing HRC (EpiHR+) cells (G) and the expression (MAGIC values) of the Emp1 gene (H). I and J, UMAP visualization and violin plot showing CSCs (Lgr5+ ISC-like) and the expression (MAGIC values) of the Lgr5 gene (J). MAGIC, Markov Affinity-based Graph Imputation of Cells. K, UMAP visualization and violin plot showing proliferative cells. Gene signatures used for the analysis are detailed in Supplementary Table S1. In the UMAP visualization, black indicates the top 20% (quantile 80) of cells based on feature expression (true) and gray indicates the remaining cells (false). The gene expression UMAP is split by the vehicle and RMC-9945 groups. L, Treatment from day 21 of established liver metastases (LiM) generated by injecting AKTP Emp1-Tom MTOs in the spleen of C57BL/6J mice. M, Percentage of Lgr5 mRNA spots detected by RNAscope on the total cell number detected in each metastasis. Each dot represents one metastasis. Vehicle n = 56, RMC-9945 n = 71. Mean ± SEM; P values are derived from unpaired t test. N, Representative example of Lgr5 mRNA FISH combined with tdTomato immunofluorescence on liver metastases sections. Scale bar, 400 μm. O, Treatment from day 15 of established liver metastases (LiM) generated by injecting AKTP MTOs Emp1-Tom in the spleen of C57BL/6J mice. P, Percentage of Lgr5 mRNA spots detected by RNAscope on the total cell number detected in each metastasis. Each dot represents one metastasis. Vehicle n = 95, RMC-9945 n = 87. Mean ± SEM; P values are derived from unpaired t test. Q, Representative example of Lgr5 mRNA FISH combined with tdTomato immunofluorescence on liver metastases sections. Scale bar, 100 μm.

6 February 2026
Verified
Other
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
PDAC and keratinization gene programs induced by KRAS activating mutations. A, Dot plot illustrating the scaled and normalized expression of selected marker genes across the different metastasis cell clusters (Louvain clustering, resolution = 0.6, SCT values). B, UMAP visualization showing PDAC basal cells (B) and epidermal keratinization (C) with black indicating the top 20% (quantile 80) of cells based on feature expression (TRUE) and gray indicating the remaining cells (FALSE). D, Heatmaps of in vitro APK CTOs and AKTP MTOs treated with vehicle or RMC-9945 for 48 hours, hierarchically clustered using the Ward D2 method based on keratinization gene list. E, Representative example of hematoxylin and eosin (H&E) staining on liver metastases treated with vehicle or RMC-9945 for 11 days. Scale bar, 50 μm. F, Representative example of E-cadherin immunofluorescence on liver metastases treated with vehicle or RMC-9945. Top scale bar, 100 μm. Bottom scale bar, 20 μm. G–I, Volcano plot showing expression differences of the EpiHR signature (G), the basal pancreatic signature (H), and keratinization genes (I) between samples with and without driver mutations in individual oncogenes and tumor-suppressor genes from the COAD TCGA patient cohort (n = 520 patients). The difference of median values (x axis) versus P values (Wilcoxon rank-sum test; y axis) are shown. J, Volcano plot of differential expression of samples with and without mutations in the KRAS signaling pathway. Genes of interest are highlighted. FC, fold change.

6 February 2026
Verified
Other
Open access
ACAlessia Centonze
Alessia Centonze
ARAdria-Jaume Roura
Adria-Jaume Roura
MNMeritxell Novillo-Font
Meritxell Novillo-Font
CGCristina Giordano
Cristina Giordano
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle
Supplementary Table S3. Gene expression related to Supplementary Figure S6B, C, G, H, I, J